Skip to main content

GRI Bio, Inc.

GRI
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001824293

No open-market purchases or sales by GRI Bio, Inc. insiders were filed in the last 90 days; 11 institutions reported holding it in 13F filings for Q2 2026, worth $164.7K in total; no superinvestor holds it.

Holders of 5% or more of GRI

Holders whose latest Schedule 13D or 13G filing reports 5% or more of GRI Bio, Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of GRI
HolderLatest formStakeChangeFirst filedLatest filingFiling
Intracoastal Capital, LLC13G/A9.99%1.10M shares0.00 ppfrom 9.99%Apr 7, 20253 filingsFeb 13, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

5 Schedule 13D and 13G filings on GRI Bio, Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on GRI
Filed (ET)FilerFormStakeChangeEvent dateFiling
Feb 13, 20264:43 PM ETIntracoastal Capital, LLCand 2 others13G/A9.99%1.10M shares0.00 ppfrom 9.99%Dec 31, 2025SEC
Feb 10, 20262:10 PM ETLincoln Alternative Strategies LLC13G/A0.00%0 shares−11.83 ppfrom 11.83%Below 5%Dec 30, 2025SEC
Dec 29, 20254:54 PM ETLincoln Alternative Strategies LLC13G11.83%1.20M sharesNewDec 12, 2025SEC
Dec 17, 20258:19 PM ETIntracoastal Capital, LLCand 2 others13G9.99%677.5K shares+5.00 ppfrom 4.99%Dec 11, 2025SEC
Apr 7, 20254:17 PM ETIntracoastal Capital, LLCand 2 others13G4.99%40.3K sharesNewBelow 5%Apr 1, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell GRI Bio, Inc. shares.

No Form 144 notices for GRI Bio, Inc. are on file.